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.4bstract 
The residues on MAP kinase kinase-1 (MAPKKI) phosphorylated by MAP kinase in vitro have been identified as Thr-291 and Thr-385. Both 
threonines are phosphorylated in PC12 cells and the ‘*P-1abelling of each residue increases after stimulation with nerve growth factor (NGF). The 
results establish that MAPKKl is a physiological substrate for MAP kinase. The two active forms of MAPKK that are resolved by Mono Q 
chromatography of PC12 cell extracts are both phosphorylated at Thr-291 and Thr-385, demonstrating that neither species is the MAPKK2 isofonn 
which lacks Thr-291. 
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1. Introduction 
MAP kinase kinase (MAPKK) is a key component of 
the mitogen-activated protein (MAP) kinase cascade, a 
signal transduction pathway of central importance in 
mediating the actions of growth factors that cause cells 
to proliferate or to differentiate [1,2]. MAPKK is a ‘dual 
specificity’ protein kinase which activates MAP kinase 
by phosphorylating a threonine and a tyrosine residue 
[3,4], and is itself activated by phosphorylation [S] cataly- 
sed by one or more MAP kinase kinase kinases 
(MAPKKKs). A MAPKKK which is activated after cell 
stimulation by growth factors is the proto-oncogene 
P74”f-1 which phosphorylates the MAPKK isoform, 
termed here MAPKKl [69], at Ser-217 and Ser-221 [lo]. 
Only the diphosphorylated derivative of MAPKKl is 
detected, even at low levels of phosphorylation by 
p74’“~1, indicating that phosphorylation of one serine 
residue is rate limiting, phosphorylation of the second 
then occurring extremely rapidly. Furthermore, 
dephosphorylation of both Ser-217 and Ser-221 is re- 
quired to inactivate MAPKKl, suggesting that phospho- 
rylation of either serine residue is sufficient for maximal 
activation. The unusual properties of this system may 
provide a mechanism for achieving significant activation 
of MAPKKl, even under conditions where ~74”~~’ is 
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only activated slightly. Ser-217 and Ser-221 are both 
phosphorylated in vivo when phaeochromocytoma 
(PC12) cells are stimulated with nerve growth factor [lo]. 
Phosphoamino acid analysis of MAPKK immunopre- 
cipitated from 32P-labelled Xenopus oocytes [l l] and 
EGF-stimulated human A431 cells [12], has revealed the 
presence of much more phosphothreonine than 
phosphoserine, indicating that the enzyme is 
phosphorylated in vivo at sites distinct from those 
phosphorylated by ~74’~‘. Here we identify the threon- 
ine residues in MAPKKl phosphorylated in nerve 
growth factor (NGF)-stimulated rat phaeochromocy- 
toma (PC12) cells and show that they correspond to the 
residues phosphorylated by MAP kinase in vitro. 
2. Materials and methods 
2.1. Materials 
The p42 isoform of murine MAP kinase (p42”*pk) was expressed in 
E. coli as a glutathione transferase fusion protein, activated with 
MAPKK from rabbit skeletal muscle [13] and assayed as described 
previously [14]. One unit of MAP kinase was that amount of activity 
which catalysed the incorporation of 1 .O nmol of phosphate into myelin 
basic protein in one min. Inactive rabbit MAPKK.1 was expressed in 
E. colias a fusion protein, with glutathione transferase at its N-terminus 
and six histidine residues at its C terminus, and purified by successive 
affinity chromatographies on glutathione-Sepharose and nickel-ni- 
trilotriacetate-agarose [lo]. Antisera to MAPKKl were raised in rab- 
bits [lo] and the sources of other materials are given in [lo]. 
2.2. Phosphorylation of MAPKKl by MAP kinase 
The incubations (1 .O ml) contained 25 mM Tris-HCl pH 7.0,O.l mM 
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EDTA, 0.1 mM EGTA, 0.02% (w/v) Brij 35, 5% (v/v) glycerol (Buffer 
A), 0.2 mg (2.8 nmol) of MAPKKl, 10 mM magnesium acetate, 0.1 mM 
[y”P]ATP (1.7 x lo6 cpm/nmol) and MAP kinase (5 U/ml). After incu- 
bation for 1 h at 3O”C, the solution was concentrated to 0.05-0.1 ml 
by centrifugation through a Centricon 30 membrane, diluted with 1 .O 
ml of Buffer A and reconcentrated. This procedure was repeated four 
times until [y”P]ATP comprised < 5% of the “P-radioactivity. 
2.3. Digestion of 3zP-labelled MAPKKI with thermolysin and 
purification of thermolytic phosphopeptides 
0.1 mg of native ‘2P-labelled MAPKKl in 0.2 ml of Buffer A 
(phosphorylated by MAP kinase) was incubated for 60 min at 37°C 
with 1.0 mg of thermolysin in 0.2 ml of 20 mM Tris-HCl pH 7.5 
containing 4 mM CaCl, and the reaction terminated with 50 ~1 of 20% 
(w/v) TCA. After standing in ice for 5 min, the suspension was centri- 
fuged for 5 min at 13,000 x g to pellet the thermolysin and undigested 
MAPKKl, and the supernatant (containing > 90% of the “P-radioac- 
tivity) was removed, diluted with two volumes of 0.1% (v/v) tri- 
fluoroacetic acid, and chromatographed on a Vydac C,, 218TP54 col- 
umn (Separations Group, Hesperia, CA, USA) equilibrated in 0.1% 
(v/v) trifluoroacetic acid pH 1.9. The column was developed with a 
linear acetonitrile gradient with an increase in acetonitrile concentra- 
tion of 0.33% per min. The flow rate was 0.8 mUmin and fractions of 
0.4 ml were collected. “P-labelled peptides were pooled and rechroma- 
tographed on the C,, column in an identical manner except hat 0.1% 
trifluoroacetic acid pH 1.9 was replaced by 10 mM ammonium acetate 
pH 6.5. 
2.4. Digestion of immunoprecipitated MAP kinase kinase with 
thermolysin 
PC12 cells were labelled with ‘2P-inorganic phosphate and MAPKKl 
was immunoprecipitated from the cell lysates or Mono Q fractions and 
analysed by SDS/PAGE as described [lo]. The 32P-labelled 44 kDa 
MAPKK band was excised, homogenised in five vol of 25 mM N- 
ethylmorpholine acetate pH 7.7 and SDS and 2-mercaptoethanol were 
added to final concentrations of 0.1% (w/v) and 5% (v/v), respectively. 
After heating for 5 min at lOO”C, the suspension was incubated for a 
further 12 h at 37”C, then centrifuged for 5 min at 13,000 x g. The 
supernatants (containing 50-70% of the ‘2P-radioactivity in the gel 
slice) were removed and dialysed for 8 h at 4°C against 25 mM 
N-ethylmorpholine acetate pH 7.7 with three changes of dialysis buffer. 
The samples were reduced to 0.3 ml in a vacuum concentrator and 
digested for 3 h at 42°C with 2.5 mg/ml thermolysin in 25 mM 
N-ethylmorpholine acetate containing 2 mM CaCl,. 
3. Results 
3.1. Iden@cation of the residues on MAPKKI 
phosphorylated by MAP kinase in vitro 
It has been reported that a MAPKK from Xenopus 
oocytes is a substrate for MAP kinase [ll], and in the 
present study rabbit MAPKKl was also found to be 
phosphorylated by MAP kinase. The initial rate of phos- 
phorylation of MAPKKl (4 PM) was 10% that of the 
standard substrate myelin basic protein (4 PM). The 
phosphorylation of MAPKKl reached 1.3 and 1.8 mol/ 
mol protein after incubation for 1 h with 5 U/ml and 20 
U/ml MAP kinase, respectively, suggesting phosphoryla- 
tion at more than one site. Phosphoamino acid analysis 
showed the presence of phosphothreonine, but no 
phosphotyrosine or phosphoserine was present (data not 
shown). 
Digestion of the native 32P-labelled enzyme (contain- 
ing 1.3 mol phosphate/m01 protein) with thermolysin 
released 90% of the 32P-radioactivity as trichloroacetic 
acid soluble phosphopeptides and chromatography on a 
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Fig. 1. Separation of “P-labelled thermolytic phosphopeptides from 
MAPKKl phosphorylated by MAP kinase. MAPKKl was 
phosphorylated to 1.3 mol/mol with MAP kinase, digested with ther- 
molysin and in (A) chromatographed on a Vydac C,, column equili- 
brated in 0.1% (v/v) trifluoroacetic acid (pH 1.9) as described in section 
2. The 32P-radioactivity (full line) was recorded continuously with an 
on-line monitor and the acetonitrile gradient is shown by the broken 
line. The two major thermolytic peptides Th-I and Th-2 (eluting at 14% 
and 10% acetonitrile, respectively) represented 66% and 23% of the 
“P-radioactivity applied to the C,, column, respectively. (B) Peptide 
Th-2 was rechromatographed asin (A) except hat trifluoroacetic acid 
was replaced by 10 mM ammonium acetate pH 6.5. 
Cl8 column at pH 1.9 revealed two 32P-labelled peptides, 
Th-1 and Th-2, eluting at 14% and 10% acetonitrile, 
respectively (Fig. 1A). Th-2 accounted for 23% and Th-1 
for 66% of the 32P-radioactivity applied to the column. 
Both peptides were purified by a further chromatogra- 
phy on the C,, column run at pH 6.5 instead of pH 1.9. 
Th- 1 eluted as a single peak at 16% acetonitrile (data not 
shown), whereas Th-2 was resolved into two compo- 
nents, Th-2a and Th-2b (Fig. 1B). 
The N-terminal sequence of peptide Th-1 
(AAETPPRPRTPGRP) was found to correspond to res- 
idues 282-295 of the mature MAPKKl protein (in which 
the initiating methionine is removed [7] and the site of 
phosphorylation was identified as Thr-291 (Fig. 2A). 
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Fig. 2. Identification of the residues in MAPKKl phosphorylated by 
MAP kinase in vitro. (A) Peptide Th-1 from Fig. 1A was further 
purified by chromatography on the C,s column in 10 mM ammonium 
acetate pH 6.5. The peptide, which eluted at 16% acetonitrile, was then 
sequenced twice on an Applied Biosystems 470A gas phase sequencer; 
firstly by conventional gas phase sequencing to identify amino acid 
residues; secondly by solid phase sequencing after coupling the peptide 
(15,000 cpm) covalently to a Sequelon arylamine membrane (Millipore, 
Watford, UK) via its carboxyl groups [13]. The figure shows 32P-radio- 
activity released and amino acid residues (single letter code) identified 
after each cycle of Edman degradation. (B) Peptide Th-2a (9,600 cpm) 
from Fig. 1B was sequenced in an identical manner to Th-1. The 
phenylthiohydantoin derivative of threonine was not detected at the 
tenth cycle in A or at the sixth cycle in B and is therefore shown in 
parentheses. In A, the 32P-radioactivity released after the third cycle of 
Edman degradation is caused by extraction of peptide which had been 
coupled to the membrane solely through the y-carboxyl of glutamic 
acid and not through the a-carboxyl at the C terminus. 
Amino acid analysis and fast atom bombardment mass 
spectrometry confhmed that the peptide terminated at 
residue 295. The N-terminal sequence of peptide Th-2a 
(the major peptide from Fig. 1B) corresponded to resi- 
dues 380 to 388 of the mature MAPKKl protein 
(LNQPSTPTH) and the site of phosphorylation was 
identified as Thr-385 (Fig. 2B). Amino acid analysis and 
fast atom bombardment mass spectrometry established 
that this peptide terminated at residue 388 (data not 
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shown). The minor phosphothreonine-containing pep- 
tide Th-2b was not obtained in pure form, but amino 
acid sequencing also revealed a single burst of 32P-radio- 
activity after the sixth cycle of Edman degradation as 
observed for Th-2a (data not shown). Th-2b may corre- 
spond to Th-2a in which the asparagine and/or glutam- 
ine residue is deamidated, which would account for its 
more acidic isoelectric point (see Fig. 4). 
3.2. Phosphorylation of MAPKK in PC12 cells 
32P-labelled PC12 cells were stimulated with NGF for 
40 min, lysed in the presence of protein phosphatase 
inhibitors and chromatographed on Mono Q to separate 
the two peaks of active MAPKK (eluting at 80-100 mM 
NaCl and 120-140 mM NaCl) from inactive MAPKK 
which does not bind to the column [ 10,151. MAPKK was 
immunoprecipitated quantitatively from each fraction 
and SDUpolyacrylamide gel electrophoresis of the im- 
munoprecipitates followed by autoradiography revealed 
a single 32P-labelled band with the molecular mass of 
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Fig. 3. Separation of thermolytic phosphopeptides generated from 
MAPKKl after immunoprecipitation from extracts of ‘2P-labelled 
PC12 cells. r2P-labelled cells were stimulated for 40 mitt with NGF, 
lysed and chromatographed on Mono Q as in [lo]. Inactive MAPKKl 
(flowthrough fractions) and the first of the two peaks of active 
MAPKKl were immunoprecipitated and digested with thennolysin as 
in section 2.4 and chromatographed on a Vydac C,, column at pH 1.9 
as in Fig. 1A. The ‘*P-radioactivity (full line) was recorded continuously 
with an on-line monitor and the acetonitrile gradient is shown by the 
broken line. A, inactive MAPKKl (MKKl); B, active MAPKKI 
(MKKl). The recovery of “P-radioactivity from each column was 90%. 
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Fig. 4. Isoelectric focussing of thermolytic peptides from MAPKKI 
phosphorylated by MAP kinase in vitro and in PC12 cells in vivo. The 
32P-labelled peptides were analysed by isoelectric focussing [28] and the 
figure shows an autoradiograph of the electrophoretogram. Lanes 1 
and 3 show peptides 2 and 1 from Fig. 3 obtained by digestion of 
MAPKKl immunoprecipitated from ‘*P-labelled PC12 cells. Lanes 2 
and 4 show peptides Th-2 and Th-1 from Fig. 1 obtained by thermolytic 
digestion of MAPKKl phosphorylated by MAP kinase in vitro. The 
major “P-1abelled band in lanes 1 and 2 corresponds to peptide Th-2a 
and the minor acidic “P-1abelled band to peptide Th-2b in Fig. 1B. The 
isoelectric points of the markers Patent blue (2.4), acetylated cyto- 
chrome C (4.0) and azurin (5.7) are also shown. 
MAPKKI (44 kDa) [lo]. This band was present in the 
flowthrough fractions containing inactive MAPKK, as 
well as both peaks of active MAPKK [lo]. 32P-radioac- 
tivity associated with the inactive MAPKK in the 
flowthrough fractions was much greater than that associ- 
ated with the two peaks of active MAPKK, and in two 
experiments was 2.3 f 0.1 -fold higher than both peaks of 
active MAPKK combined. 
The immunoprecipitated MAPKK protein was di- 
gested with thermolysin and chromatographed on a Cl8 
column. The digests of inactive MAPKK (Fig. 3A), the 
first peak of active MAPKK (Fig. 3B) and the second 
peak of active MAPKK (data not shown) each contained 
three major 32P-labelled peptides eluting at 33, 36 and 70 
min, while both peaks of active MAPKK contained an 
additional component eluting after 5 min. The latter was 
a phosphoserine-containing peptide which was also 
generated by thermolytic digestion of MAPKKl that 
had been phosphorylated by ~74’“~~’ in vitro (data not 
shown) and therefore contains the peptides comprising 
residues 217 and 221 (see section 1). The peptides eluting 
at 33, 36 and 70 min only contained phosphothreonine 
(data not shown). 
The component (peptide 1) eluting after 70 min in Fig. 
3A comigrated in isoelectric focussing experiments with 
peptide Th-1 from Fig. 1A (Fig. 4, lanes 3 and 4). Fur- 
thermore, when re-chromatographed on the C,, column 
this phosphopeptide now eluted at 43 min, the same time 
as peptide Th-1 (Fig. 1A). Also, the addition of SDS (1%) 
to peptide Th- 1 from Fig. 1A greatly retarded its elution 
from the C,* column (data not shown). The abnormal 
elution of this peptide during the first Cl8 chromatogra- 
phy (Fig. 3A) can therefore be explained by the presence 
of SDS in the thermolytic digest (see section 2) which 
binds to the peptide (presumably to the three arginine 
residues) retarding its elution from the C,* column. This 
was confirmed by phosphorylating MAPKKI in vitro 
with MAP kinase followed by SDS/polyacrylamide gel 
electrophoresis and thermolytic digestion as described 
above. Chromatography of this digest on a C,s column 
yielded the same pattern of phosphopeptides to that ob- 
served in Fig. 3A (data not shown). SDS clearly dissoci- 
ates from the peptide during either isoelectric focussing 
or re-chromatography. The peptide eluting at 70 min 
(Fig. 3) was subjected to solid phase sequencing and, 
consistent with its identity as Th- 1, 32P-radioactivity was 
released at the tenth cycle of Edman degradation (Fig. 
5A). This demonstrates that Thr-291 of MAPKKI is 
phosphorylated in PC12 cells after stimulation by NGF. 
The peptide eluting after 33 min in Fig. 3 comigrated 
with peptide Th-2 from Fig. 1A during both C,* chrom- 
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Fig. 5. Thr-291 and Thr-385 of MAPKKl are phosphorylated in NGF- 
stimulated PC12 cells. (A) Peptide 1 from Fig. 3 (1200 cpm) was analy- 
sed by solid phase sequencing as in Fig. 2. The figure shows 32P- 
radioactivity released after each cycle of Edman degradation. Peptide 
1 comigrated in isoelectric focussing experiments (Fig. 4) with the pep- 
tide comprising residues 282-295 of MAPKKl, the sequence of which 
is shown on the abscissa. The reason why some “P-radioactivity is 
released after the third cycle of Edman degradation is explained in the 
legend to Fig. 2. (B) Peptide- from Fig. 3 (2,100 cpm) was analysed 
by solid phase sequencing as in A. This peptide comigrated in isoelectric 
focussing experiments (Fig. 4) with the peptide comprising residues 
38tS388 of MAPKKl, the sequence of which is shown on the abscissa. 
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atography and isoelectric focussing (Fig. 4, lanes 1 and 
2). Both in vitro and in vivo-labelled peptides exhibited 
a major and a minor band upon isoelectric focussing, 
which correspond to peptides Th-2a and Th-2b respec- 
tively (Fig. 4). The peptide eluting at 33 min in Fig. 3 was 
subjected to solid phase sequencing and, consistent with 
its identity as Th-2, 32P-radioactivity was only released 
after the 6th cycle of Edman degradation (Fig. SB). This 
demonstrates that Thr-385 is phosphorylated in vivo in 
response to NGF. The proportions of the two compo- 
nents eluting at 33 min and 36 min varied from prepara- 
tion to preparation and the latter also showed two 32P- 
labelled bands in isoelectric focussing experiments which 
comigrated with peptides Th-2a and Th-2b (data not 
shown). The peptide eluting at 36 min therefore com- 
prises peptides Th-2a and Th-2b plus bound SDS. 
3.3. Effect of phosphorylation by MAP kinase on the 
activity of MAPKKl 
The finding that the inactive MAPKK in the 
flowthrough fractions from Mono Q was 
phosphorylated at both Thr-291 and Thr-385 in PC12 
cells implied that phosphorylation of these residues by 
MAP kinase does not activate MAPKK. This was con- 
firmed by phosphorylating MAPKKl with MAP kinase 
in vitro. Bacterially expressed MAPKKl was virtually 
(but not completely) inactive [lo] and phosphorylation 
to 1.8 mol/mol by MAP kinase did not increase this very 
low basal level of activity. In contrast, maximal phos- 
phorylation of MAPKKl by ~74’“‘~’ resulted in a 7000- 
fold increase in activity [lo]. 
4. Discussion 
The sequence surrounding the residue (Thr-291) in 
MAPKKl phosphorylated most rapidly by MAP kinase 
(Pro-Arg-Thr-Pro) is identical to that surrounding the 
major phosphorylation site in myelin basic protein [16], 
the substrate normally used to assay MAP kinase. A 
similar sequence (Pro-Arg-Ser-Pro) surrounds the resi- 
due in the TH-3 and TH-4 forms of human tyrosine 
hydroxylase which are the alternatively spliced variants 
of this enzyme phosphorylated most rapidly by MAP 
kinase [17]. MAP kinase substrates possessing an argin- 
ine residue immediately N-terminal to the phosphoryla- 
tion site may therefore be phosphorylated preferentially. 
Pro-Xaa-Ser/Thr-Pro sequences are not only found at 
the two MAP kinase phosphorylation sites in MAPKKl, 
but also in other proteins thought to be physiological 
substrates for MAP kinase, such as MAPKAP kinase-2 
[131. 
However, although the C-terminal proline is essential 
for phosphorylation by MAP kinase, the N-terminal 
proline is not since LetVIle-Xaa-Ser/Thr-Pro sequences 
are found in other physiological substrates, such as 
MAPKAP kinase-1 [18], c-jun [19] and stathmin [20]. In 
the case of stathmin, the major site phosphorylated by 
MAP kinase in vitro lies in an Ile-Xaa-Ser-Pro sequence 
and the minor site in a Pro-Xaa-Ser-Pro sequence [20]. 
Thr-291 and Thr-385 represent two of the sites in 
MAPKKl that are phosphorylated in PC12 cells and in 
several experiments the 32P-labelling of these residues 
increased by twofold to threefold after stimulation for 40 
min with NGF (data not shown). This indicates that 
MAPKKl is phosphorylated by MAP kinase in vivo, but 
the physiological role is unclear because MAP kinase 
does not activate MAPKKl. We have also been unable 
to detect any significant effect of Thr-291 and Thr-385 
phosphorylation on the activity of activated MAPKKl, 
or on its rate of activation by ~74”“’ or rate of inactiva- 
tion by the catalytic subunit of PP2A. Other proteins that 
lie upstream of MAP kinase in this growth factor-stimu- 
lated pathway also appear to be phosphorylated by 
MAP kinase in vivo, such as ~74’“~~’ [21] and the EGF 
receptor [22]. The effects of MAP kinase phosphoryla- 
tion on these two proteins is also unknown. Perhaps the 
phosphorylation by MAP kinase of ‘upstream’ compo- 
nents in this signalling pathways does not alter their 
activity directly, but their subcellular location or ability 
to interact with other proteins. 
MAPKK is inactive in unstimulated rat PC12 cells. 
Activation is maximal five min after stimulation with 
NGF and maintained at a similar level for at least 90 min 
[ 151. When the cells are lysed in the presence of phosphat- 
ase inhibitors and chromatographed on Mono Q, most 
of the inactive MAPKK does not bind to the column 
whereas activated MAPKK is retained and eluted at two 
peak. The second peak accounts for c 20% of the 
MAPKK activity after stimulation with NGF for 5 min, 
but its proportion increases to 40-50% after 40 min 
[10,15]. The two active forms of MAPKK comigrate on 
SDS-polyacrylamide gels in immunoprecipitation [lo] or 
immunoblotting experiments and are inactivated simi- 
larly by the MAPKKl-antisera (data not shown). Fur- 
thermore, both peaks of active MAPKK are 
phosphorylated at Ser-217 and Ser-221 [lo] as well as at 
Thr-291 and Thr-385. Thus neither species corresponds 
to the MAPKK2 isoform which lacks Thr-291 [23-251. 
The two peaks of MAPKK activity may either represent 
very closely related isoforms, or the second peak may be 
derived from the first by an as yet unidentified post- 
translational modification. Thr-291 is also absent in the 
MAPKKs from Xenopus eggs [26] and Drosophila [27] 
that have been identified. However, the Pro-Ser-Thr-Pro 
sequence surrounding Thr-385 is totally conserved in all 
MAPKKs cloned to date from vertebrates and inverte- 
brates. 
If it is assumed that Thr-291 and Thr-385 are 
phosphorylated to the same extent in the inactive and 
active forms of MAPKK, then it can be calculated from 
the total amount of 32P-radioactivity associated with in- 
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active MAPKK in the Mono Q flowthrough fractions 
(which is phosphorylated at two residues-Thr-291 and 
Thr-385) and the two active MAPKK peaks retained by 
the column (which are phosphorylated at four residues- 
Ser-217, Ser-221, Thr-291 and Thr-385) that only 20% of 
the MAPKK is converted to the active form after stimu- 
lation with NGF. In fact, the extent of activation may 
be even lower, because some inactive MAPKK appears 
to bind to Mono Q and elute with the first peak of active 
MAPKK (Y. Saito unpublished experiments). This ex- 
plains why MAPKK immunoprecipitated from 32P-la- 
belled cells contain far less phosphoserine than 
phosphothreonine [l 1,121. Nevertheless, this low degree 
of activation is sufficient to fully activate both p42”“Pk 
and p44mapk, asshown by gel-mobility shift experiments 
(D. Cross and P. Cohen, unpublished observations). 
This emphasizes the high degree of amplification inher- 
ent in this protein phosphorylation cascade and suggests 
that only trace activation of MAPKKKs, such as ~74’“~-‘, 
may be sufficient to generate the MAPKK activity 
needed for the full activation of MAP kinase. 
The activation of ~74’“~~’ is normally assayed after its 
immunoprecipitation from extracts of cells that have 
been stimulated with a growth factor or transformed 
with an oncogene. The finding that MAPKK is a sub- 
strate for at least two protein kinases in vivo and in vitro 
indicates that it is potentially dangerous to assay ~74’“~~’ 
solely by the phosphorylation of MAPKK, because of 
the risk of contamination of the immunoprecipitates 
with MAP kinase and/or other protein kinases that phos- 
phorylate MAPKK at residues other than those involved 
in activation. When assaying ~74’“~-‘, it would seem es- 
sential to measure the activation of MAPKK, rather 
than its phosphorylation, or at least to ensure that the 
MAPKK substrate has been phosphorylated on serine 
and not on threonine residues. 
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